7,12-Dimethylbenz(a)anthracene
7,12-Dimethylbenz(a)anthracene[1] | |
---|---|
7,12-dimethylbenzo[b]phenanthrene | |
Identifiers | |
CAS number | 57-97-6 |
PubChem | 6001 |
ChemSpider | 5779 |
ChEBI | CHEBI:254496 |
ChEMBL | CHEMBL329673 |
Jmol-3D images | Image 1 |
| |
| |
Properties | |
Molecular formula | C20H16 |
Molar mass | 256.34104 |
Melting point | 122–123 °C |
Hazards | |
R-phrases | R45 R22 |
S-phrases | S53 S36/37 S45 |
Main hazards | T (Toxic) |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
Infobox references | |
7,12-Dimethylbenz(a)anthracene is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] Also known as 7,12-dimethylbenz[α]anthracene or DMBA, this substance is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator by making necessary mutations. Tumor promotion can be induced with treatments of TPA (12-O-tetradecanoylphorbol-13-acetate) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
References
- ↑ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
- ↑ Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y. (2001) Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ. Jpn J Pharmacol 86:302-309. Link
- ↑ Sung YM, He G, Fischer, SM. (2005) Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development. Cancer Res 65:9304-9311